Angiogenic signaling pathways and anti-angiogenic therapy for cancer

ZL Liu, HH Chen, LL Zheng, LP Sun… - Signal transduction and …, 2023 - nature.com
Angiogenesis, the formation of new blood vessels, is a complex and dynamic process
regulated by various pro-and anti-angiogenic molecules, which plays a crucial role in tumor …

Predictive biomarkers for checkpoint inhibitor-based immunotherapy in hepatocellular carcinoma: where do we stand?

A Rizzo, AD Ricci, A Di Federico, G Frega… - Frontiers in …, 2021 - frontiersin.org
Hepatocellular carcinoma (HCC) remains the sixth most commonly diagnosed malignancy
worldwide, still representing an important cause of cancer-related death. Over the next few …

[HTML][HTML] Knowledge map** of immunotherapy for hepatocellular carcinoma: a bibliometric study

J Shen, H Shen, L Ke, J Chen, X Dang, B Liu… - Frontiers in …, 2022 - frontiersin.org
Background Hepatocellular carcinoma (HCC) is one of the most common malignant tumors,
and many patients are diagnosed with advanced disease. The treatment of advanced liver …

Biomarkers for breast cancer immunotherapy: PD-L1, TILs, and beyond

A Rizzo, AD Ricci - Expert opinion on investigational drugs, 2022 - Taylor & Francis
ABSTRACT Introduction Immune checkpoint inhibitors (ICIs) have recently entered into the
therapeutic scenario of metastatic breast cancer. However, only a proportion of patients …

Which role for predictors of response to immune checkpoint inhibitors in hepatocellular carcinoma?

A Rizzo, A Cusmai, G Gadaleta-Caldarola… - Expert review of …, 2022 - Taylor & Francis
Introduction Hepatocellular carcinoma (HCC) remains a frequently diagnosed malignancy
worldwide, still representing an important cause of cancer-related death. Recent years have …

Atezolizumab-bevacizumab plus Y-90 TARE for the treatment of hepatocellular carcinoma: preclinical rationale and ongoing clinical trials

A Di Federico, A Rizzo, R Carloni… - Expert Opinion on …, 2022 - Taylor & Francis
Introduction The treatment algorithm of advanced hepatocellular carcinoma (HCC) has
evolved since the introduction of immunotherapy. The IMbrave150 trial set atezolizumab …

Immune-based combinations for metastatic triple negative breast cancer in clinical trials: current knowledge and therapeutic prospects

A Rizzo, AD Ricci, L Lanotte, L Lombardi… - Expert opinion on …, 2022 - Taylor & Francis
Introduction Immune checkpoint inhibitor (ICI) monotherapy appears to be effective in a
small cohort of patients with metastatic triple negative breast cancer (mTNBC). This supports …

PD-L1, TMB, and other potential predictors of response to immunotherapy for hepatocellular carcinoma: how can they assist drug clinical trials?

A Rizzo, AD Ricci - Expert opinion on investigational drugs, 2022 - Taylor & Francis
Introduction Hepatocellular carcinoma (HCC) represents the sixth most commonly
diagnosed malignancy worldwide, accounting for millions of deaths annually. Despite …

Activation of Piezo1 contributes to matrix stiffness‐induced angiogenesis in hepatocellular carcinoma

M Li, X Zhang, M Wang, Y Wang, J Qian… - Cancer …, 2022 - Wiley Online Library
Background Despite integrin being highlighted as a stiffness‐sensor molecule in matrix
stiffness‐driven angiogenesis, other stiffness‐sensor molecules and their mechanosensory …

Ladiratuzumab vedotin for metastatic triple negative cancer: preliminary results, key challenges, and clinical potential

A Rizzo, A Cusmai, S Acquafredda… - Expert opinion on …, 2022 - Taylor & Francis
Several potential therapeutic targets for antibody drug conjugates (ADCs) have been
highlighted in breast cancer, including, among the others, HER2, TROP-2, PTK7, and LIV-1 …